In spite of the successful use of monoclonal antibodies (mAbs) in clinic for tumor treatment,
their applications are still hampered in therapeutic development due to limitations, such as …

Nowadays, the targeted imaging probe and drug delivery systems are the novel
breakthrough area in the nanomedicine and treatment of various diseases. Conjugation of …

The development of monoclonal antibody treatments for successful tumor-targeted therapies
took several decades. However, the efficacy of antibody-based therapy is still confined and …

In the last decade, cancer immunotherapies have produced impressive therapeutic results.
However, the potency of immunotherapy is tightly linked to immune cell infiltration within the …

The development of tumor-targeted therapies using monoclonal antibodies has been
successful during the last 30 years. Nevertheless, the efficacy of antibody-based therapy is …

The use of antibodies in cancer therapy has come a long way since the day Paul Ehrlich
described the concept and Kohler and Milstein devised the hybridoma technology to bring …

Recombinant antibodies such as nanobodies are progressively demonstrating to be a valid
alternative to conventional monoclonal antibodies also for clinical applications. Furthermore …

Nanobodies are the smallest fragments of naturally occurring single-domain antibodies that
have evolved to be fully functional in the absence of a light chain. Nanobodies are strictly …

Targeted therapy is a fast evolving treatment strategy to reduce unwanted damage to
healthy tissues, while increasing efficacy and specificity. Driven by state-of-the-art …

The development of targeted medicine has greatly expanded treatment options and spurred
new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging …